Successful use of the Satera™ Ablation System aims to improve chronic heart failure NEW YORK, March 1, 2021 /PRNewswire/ — Axon Therapies, a Coridea portfolio company focused on addressing a root cause of heart failure, today announced the treatment of the first patient in the randomized, controlled REBALANCE-HF IDE feasibility trial. The trial […]